Dr. Manish Doshi – President & CEO of Envision Scientific Pvt. Ltd. has been very upbeat about the technology development using nano sized drug molecules. He has been conferred honorary Doctors degree by Cosmopolitan University, Missouri, USA – same which has felicitated contributors like Nelson Mandela and Gunther von Hagens for their contributions to society.
Dr. Manish Doshi says that Nano Technology will change the treatment options for Coronary Heart
Disease. The company has developed Nano particle based Polymer free Drug Eluting stent (npDES) while Nano Drug Eluting Balloon (npDEB) is being developed in their other company - Concept Medical Research (CMRPL) for delivering the most widely accepted drug – Sirolimus in vessels. This method will help in dealing with current complications associated with coronary artery treatment. The newly designed Products and Equipments to do these sophisticated coatings have been applied for patent by the company.
It is proven fact that Polymers in Drug Eluting Stents (DES) create problems in the treatment. The company has designed product which eliminates use of polymer with sustained drug release in tissue. Animal trials conducted at Dr. Renu Virmani’s Center in Washington D.C, have given very positive results. Currently npDES is undergoing Animal trial at Thoraxcenter, Rotterdam, Netherlands under Prof. Patrick Serryus, world renowned Interventional cardiologist.
The company has plans to initiate FIM (First-in-Man)
Drug Eluting Balloons are fast catching up as the treatment of choice but has inherent problems of coating drug on balloon surface without polymers. With conversion of drug into nano size and enclosing it inside Excipient significantly enhances the drug delivery to the coronary artery tissue. This will reduce complexity of procedure and simplify the treatment option which may include long term medications.
Dr. Doshi says that Envision Scientific (ESPL) & Concept Medical (CMRPL) are a new entrant against the current big boys like Cordis, Abbott, Medtronic and Boston Scientific, but with its IP Portfolio and practical design will create a standing for itself. Currently, ESPL & CMRPL are involved in finalizing the product portfolio.